Prevention & care

Stomach cancer: gastric types, H. pylori, endoscopy, biomarkers, and eating after treatment

11 sources · Latest source check 2026-10-08 UTC

On this page

The stomach mixes food with digestive juices before passing it into the intestine. Most stomach cancers are adenocarcinomas arising in glandular lining cells. Gastric lymphomas, stromal tumors and neuroendocrine tumors are different families. This page mainly concerns adenocarcinoma while making those important distinctions.[1]

Several labels describe different aspects of a gastric diagnosis

Several labels describe different aspects of a gastric diagnosis
Label	Meaning
Cardia / non-cardia	Location near the esophageal junction or elsewhere in the stomach.[1]
Intestinal / diffuse	Microscopic adenocarcinoma patterns.[1]
Gastric lymphoma	A lymphoid cancer located in the stomach.[1]
GIST / neuroendocrine tumor	Other tissue families with separate care evidence.[1]
Stage	Depth, nodes and distant spread, rather than cell family alone.[6]

The gastroesophageal junction needs its precise location and family

NCI describes junctional adenocarcinoma where the esophagus meets the stomach. Its pathway can overlap gastric or esophageal care. A nearby location does not erase the need to identify the actual primary site and tissue family when interpreting a study or pathology report.[1]

Risk factors differ across stomach locations

NCI links H. pylori particularly with middle and lower stomach cancer, and reflux or obesity with upper-stomach cancer. Family history, certain inherited syndromes, atrophic gastritis and smoking can also matter. A risk factor changes probability; it is not a diagnosis or proof of why one person became ill.[2]

H. pylori is an infection, not a synonym for stomach cancer

NCI describes chronic infection as a major risk context that can lead to inflammatory and precancerous changes in some people. Treatment can reduce risk. Infection assessment, confirmation of eradication and investigation of concerning symptoms remain separate clinical questions.[2]

Prevention benefit coexisted with more adverse events

The trial reported mostly mild adverse events in 53.0% versus 19.1%. Its cancer endpoint is not proof that the same absolute benefit applies to every country, risk group or antibiotic regimen. A dated prevention study does not determine the appropriate contemporary eradication treatment for an individual.[3]

Indigestion alone cannot identify a stomach-cancer family or stage

NCI describes indigestion, appetite changes, discomfort and other symptoms that overlap many conditions. Weight loss, blood in stool, vomiting or swallowing difficulty need assessment. Early cancer can have few symptoms. A checklist cannot establish or exclude cancer, and ignoring persistent changes can delay investigation.[4]

Looking at the lining and examining tissue answer different questions

NCI describes upper endoscopy with biopsy, allowing inspection and removal of a sample for microscopic examination. Blood or stool testing can identify possible bleeding but does not replace tissue classification. The sample can also support H. pylori assessment and biomarker testing.[5]

Depth through the wall matters alongside nodes and distant spread

NCI explains the stomach wall’s layers and how invasion beyond the lining contributes to stage. A cancer’s visible diameter is not its full stage. Endoscopic ultrasound, imaging and selected operative assessment can clarify different aspects of extent; this page does not interpret a personal stage.[6][5]

HER2, mismatch repair and PD-L1 findings need their specific definitions

NCI describes tests for proteins, repair-related changes and other tumor features that may influence treatment options. A positive biomarker is not a guarantee of response. Ask which assay and threshold were used, what evidence applies to the treatment setting, and whether the finding concerns tumor tissue or inherited risk.[5]

CLDN18.2 is another treatment-specific marker

FDA’s October 2024 notice describes zolbetuximab with chemotherapy for specified adults with CLDN18.2-positive, HER2-negative, advanced unresectable or metastatic gastric/junctional adenocarcinoma. It also records serious adverse reactions including vomiting and nausea. This illustrates why an older general biomarker list is not comprehensive; it does not establish personal eligibility or rank medicines.[7]

Endoscopic removal and gastrectomy have different scopes

NCI describes endoscopic removal in selected early lining-confined settings, and subtotal or total gastrectomy in others. Total removal reconnects the esophagus with the intestine. Neither procedure name supplies its complete suitability, recurrence risk or functional consequences; the intended extent and alternatives need explanation.[8]

Treatment before and after surgery has different purposes

NCI distinguishes neoadjuvant treatment before surgery from adjuvant treatment aimed at reducing recurrence afterward. Radiation, systemic medicines and clinical trials have selected roles. A list of available treatments is not a comparative ranking or evidence that every combination benefits every tissue family.[8]

Eating and nutrient absorption may change

NCI describes reduced ability to eat enough or absorb nutrients after stomach cancer and treatment. A dietitian can help adapt meal size, frequency and nutrition. This is a functional care need, not simply a question of choosing a fashionable diet. Ask how weight changes and nutritional problems will be assessed.[9]

Follow-up can create emotional and financial burdens

NCI describes fear of recurrence, body-image changes and costs such as transport, medicines and time spent at appointments. Practical and psychological support belong alongside cancer checks. The care plan should identify who can help with these difficulties rather than leaving them outside the definition of recovery.[9]

A US average-risk statement is not a worldwide prohibition

NCI identifies family history, certain syndromes, gastric atrophy and origin from higher-incidence countries among settings where endoscopic screening may be considered. Benefits and procedure harms still need assessment. A normal screening result does not dismiss symptoms, and selected surveillance does not establish that everyone needs repeated endoscopy.[10]

Opening a blockage can help eating without curing the cancer

NHS distinguishes cancer removal from procedures aimed at relieving obstruction. It describes specialist follow-up, dietary support and palliative care when needed. Concern about symptoms or adverse effects should be raised between appointments; symptom control and other treatment can have complementary goals.[11]

Evidence & uncertainty

Screening decisions depend on population and risk. The inspected US explanation does not describe routine screening for average-risk adults, while identifying selected higher-risk settings. H. pylori prevention evidence also depends on the study population; an infection-associated risk does not make cancer inevitable or justify unsupervised antibiotics.[10][2]

Selected-source overview · Independent review pending

Published questions

Is gastric MALT lymphoma the same disease as stomach adenocarcinoma?

Selected-source overview · Independent review pending. Read the evidence context.

It is a lymphoid cancer with a different tissue family.[1]

Evidence behind this answer

What Is Stomach Cancer?
agency condition or prevention explanation · Date not stated
Selected relevant original official page passages inspected · Adenocarcinoma, location, microscopic patterns and other families